CN115634174A - Soothing and anti-allergy composition for skin, preparation method thereof and cosmetic - Google Patents
Soothing and anti-allergy composition for skin, preparation method thereof and cosmetic Download PDFInfo
- Publication number
- CN115634174A CN115634174A CN202211072847.1A CN202211072847A CN115634174A CN 115634174 A CN115634174 A CN 115634174A CN 202211072847 A CN202211072847 A CN 202211072847A CN 115634174 A CN115634174 A CN 115634174A
- Authority
- CN
- China
- Prior art keywords
- skin
- parts
- soothing
- composition
- allergy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
The application relates to the field of cosmetics, in particular to a soothing and anti-allergy composition for skin, a preparation method thereof and a cosmetic. The application provides a soothing and anti-allergy composition for skin, which comprises the following components in parts by weight: 1-10 parts of prinsepia utilis royle oil, 0.05-0.5 part of dipotassium glycyrrhizinate, 0.1-2 parts of dihydroavenyl anthranilic acid D and 1-5 parts of saffron extract. According to the soothing and anti-allergy composition for skin, the prinsepia utilis royle oil, the dipotassium glycyrrhizinate, the dihydrooat acyl anthranilic acid D and the crocus sativus extract are compounded according to the proportion, so that the synergistic effect is realized, and the soothing and anti-inflammatory effects are greatly improved.
Description
Technical Field
The application relates to the field of cosmetics, in particular to a soothing and anti-allergy composition for skin, a preparation method thereof and a cosmetic.
Background
Currently, some people have sensitive skin or are susceptible to allergy, and therefore, there is a need for cosmetic products that are less irritating or that have soothing anti-allergy effects.
Disclosure of Invention
The purpose of the embodiments of the present application is to provide a novel soothing and anti-allergy composition for skin, a preparation method thereof and a cosmetic.
In a first aspect, the present application provides a soothing and anti-allergy composition for skin, comprising, in parts by mass:
1-10 parts of prinsepia utilis royle oil; 0.05-0.5 part of dipotassium glycyrrhizinate; 0.1-2 parts of dihydroavenyl anthranilic acid D; 1-5 parts of crocus sativus extract.
According to the soothing and anti-allergy composition for skin, the prinsepia utilis royle oil, the dipotassium glycyrrhizinate, the dihydroavenyl anthranilic acid D and the crocus sativus extract are compounded according to the proportion, so that the synergistic effect is realized, and the soothing and anti-inflammatory effects are greatly improved.
In other embodiments of the present application, the soothing anti-sensitivity composition for skin further comprises: glycerol, propylene glycol, xanthan gum, allantoin, isododecane, glyceryl stearate, PEG-10 stearate, and phenoxyethanol.
In other embodiments of the present application, a soothing anti-allergy composition for skin comprises, in parts by mass:
5-10 parts of glycerol, 3-10 parts of propylene glycol, 0.1-1.0 part of xanthan gum, 0.05-0.5 part of allantoin, 1-10 parts of isododecane, 1-3 parts of glycerol stearate, 1-3 parts of PEG-10 stearate and 0.2-0.8 part of phenoxyethanol.
In other embodiments of the present application, the soothing anti-allergy composition for skin further comprises water.
In other embodiments of the present application, the total parts of the soothing and anti-allergy composition for skin is 100 parts by weight, and the part of water is the total part minus the balance of the sum of prinsepia utilis royle oil, dipotassium glycyrrhizinate, dihydroavenoyl anthranilic acid D, saffron extract, glycerin, propylene glycol, xanthan gum, allantoin, isododecane, glyceryl stearate, PEG-10 stearate, and phenoxyethanol.
In a second aspect, the present application provides a method of preparing a soothing and anti-allergy composition for skin, comprising:
heating 0.05-0.5 parts of dipotassium glycyrrhizinate to 80-95 ℃ according to the mass parts, and preserving heat for 25-45min to obtain a first solution;
heating 1-10 parts of prinsepia utilis royle oil to 80-95 ℃ to obtain second liquid;
mixing the first solution and the second solution, homogenizing, cooling to 40-50 deg.C, adding 0.1-2 parts of dihydroavenoyl anthranilic acid D, and 1-5 parts of stigma croci Sativi extract.
In other embodiments of the present application, the first liquid is prepared by adding water, glycerol, propylene glycol, xanthan gum, allantoin, and dipotassium glycyrrhizinate, mixing, heating to 80-95 deg.C, and maintaining the temperature for 25-45min.
In other embodiments of the present application, isododecane, glyceryl stearate, PEG-100 stearate, and Prinsepia utilis oil were also added to the second liquid, mixed uniformly with the Prinsepia utilis oil, and heated to 80-95 ℃. In other embodiments of the present application, the crocus sativus extract solution has a mass concentration ranging from 1% to 10%.
In other embodiments of the present application, after the first liquid and the second liquid are mixed and homogenized, phenoxyethanol is further added, and the mixture is uniformly mixed with the dihydroavenyl anthranilic acid D and the crocus sativus extract.
In a third aspect, the present application provides a cosmetic comprising the above soothing anti-allergy composition for skin or the soothing anti-allergy composition for skin prepared by the above preparation method of the soothing anti-allergy composition for skin.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions of the embodiments of the present application will be clearly and completely described below, and it is obvious that the described embodiments are some embodiments of the present application, but not all embodiments.
Thus, the following detailed description of the embodiments of the present application is not intended to limit the scope of the claimed application, but is merely representative of selected embodiments of the application. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present application.
The present embodiments provide a soothing and anti-allergy composition for skin, comprising:
prinsepia utilis Royle oil, dipotassium glycyrrhizinate, dihydrooat acyl anthranilic acid D and crocus sativus extract.
Soothing, generally, refers to the ability to relieve the symptoms of redness, fever, stinging and the like of the skin. These problems are usually caused by external stimuli and are generally accompanied by the development of inflammation.
The crocus sativus extract effectively promotes the synthesis of filaggrin, thereby playing a role in retaining water and ensuring the water content of the horny layer. The earliest and most important inflammatory medium in the inflammatory reaction process of skin is pro-inflammatory cytokine TNF alpha, the TNF alpha can activate NF-kB, simultaneously generates and releases a large amount of inflammatory factors such as 1L-1 beta, 1L-6, 1L-8 and the like, and stimulates inflammatory linkage reaction, and the crocus sativus extract can remarkably reduce the concentration of the inflammatory factor TNF alpha, avoid the opening of NF-KB signal channels, and further reduce the inflammatory reaction.
Dihydroaavenoanthranilic acid D inhibits histamine and prevents inflammatory reactions, thereby reducing the clinical symptoms associated with dry and itchy skin.
Prinsepia utilis Royle oil is originated from Shangrira region of Yunnan, and is often given as a gift to families with newborn infants by local minority nationalities for nursing the buttocks of infants and preventing chapped skin in winter. The unique fatty acid proportion of the prinsepia utilis royle oil enables the prinsepia utilis royle oil to be easily absorbed by skin, has a certain protection effect on cell viability reduction caused by UVB irradiation, and can obviously inhibit the generation of inflammatory factor interleukin (1L-8). The unique fatty acid proportion of the prinsepia utilis royle oil can obviously improve the moisture retention of the skin, so that the skin is smoother and healthier. The skin care product of prinsepia utilis royle oil can increase the physiological lipid content and is more beneficial to the recovery of the skin barrier. It can be used for adjuvant treatment of dry and wet sensitive skin.
Licorice is a traditional soothing herb, and has anti-tumor, anti-bacterial, anti-viral, anti-inflammatory and immunomodulatory properties. Glycyrrhetinic acid and glycyrrhizic acid are specific compounds isolated from licorice. Dipotassium glycyrrhizinate is dipotassium glycyrrhizinate, and is an anti-inflammatory agent widely applied. It has been found that dipotassium glycyrrhizinate has an effect of improving atopic dermatitis.
The four components of prinsepia utilis royle oil, dipotassium glycyrrhizinate, dihydro avenyl anthranilic acid D and saffron extract are compounded to realize synergistic interaction, so that the soothing and anti-inflammatory effects are greatly improved.
Further, in some embodiments herein, a soothing and anti-allergy composition for skin comprises, in parts by mass:
1-10 parts of prinsepia utilis royle oil; 0.05-0.5 part of dipotassium glycyrrhizinate; 0.1-2 parts of dihydroavenyl anthranilic acid D; 1-5 parts of crocus sativus extract.
The four components of prinsepia utilis royle oil, dipotassium glycyrrhizinate, dihydrooat acyl anthranilic acid D and saffron extract can achieve the effects of 2+2 > 4 and 1+3 > 4 in the matching proportion, and the effects of relieving and resisting inflammation are achieved.
The 2+2 > 4 and the 1+3 > 4 mean that the four components are matched with any two or three of the components, and the effects of relieving and resisting inflammation are lower than those of the scheme of the application.
Further optionally, in some embodiments herein, the soothing anti-allergy composition for skin comprises, in parts by mass:
1.1-9.9 parts of prinsepia utilis royle oil; 0.06-0.49 parts of dipotassium glycyrrhizinate; 0.2-1.9 parts of dihydrooat acyl anthranilic acid D; 1.1-4.9 parts of crocus sativus extract.
Further optionally, in some embodiments herein, the soothing anti-allergy composition for skin comprises, in parts by mass:
1.5-9.5 parts of prinsepia utilis royle oil; 0.1-0.45 part of dipotassium glycyrrhizinate; 0.3-1.8 parts of dihydrooat acyl anthranilic acid D; 1.5-4.5 parts of crocus sativus extract.
Illustratively, the soothing and anti-allergy composition for skin comprises the following components in parts by weight:
2, 3, 4, 5, 6, 7, 8 and 9 parts of prinsepia utilis royle oil; 0.15 part of dipotassium glycyrrhizinate, 0.2 part of dipotassium glycyrrhizinate, 0.25 part of dipotassium glycyrrhizinate, 0.3 part of dipotassium glycyrrhizinate, 0.35 part of dipotassium glycyrrhizinate and 0.4 part of dipotassium glycyrrhizinate; dihydroavenoyl anthranilic acid D0.5, 0.7, 0.9, 1.1, 1.2, 1.5, 1.8 parts; 2.0, 2.5, 3.0, 3.5 and 4.0 parts of crocus sativus extract.
Further, in some embodiments herein, the soothing anti-sensitivity composition for skin further comprises: glycerol, propylene glycol, xanthan gum, allantoin, isododecane, glyceryl stearate, PEG-10 stearate, and phenoxyethanol.
Further, in some embodiments herein, a soothing and anti-allergy composition for skin comprises, in parts by mass:
5-10 parts of glycerol, 3-10 parts of propylene glycol, 0.1-1.0 part of xanthan gum, 0.05-0.5 part of allantoin, 1-10 parts of isododecane, 1-3 parts of glycerol stearate, 1-3 parts of PEG-10 stearate and 0.2-0.8 part of phenoxyethanol.
Further optionally, in some embodiments herein, the soothing anti-allergy composition for skin comprises, in parts by mass:
5.5 to 9.5 portions of glycerin, 3.5 to 9.5 portions of propylene glycol, 0.2 to 0.9 portion of xanthan gum, 0.06 to 0.48 portion of allantoin, 1.5 to 9.5 portions of isododecane, 1.1 to 2.9 portions of glycerol stearate, 1.1 to 2.9 portions of PEG-10 stearate and 0.3 to 0.7 portion of phenoxyethanol.
Illustratively, the soothing and anti-allergy composition for skin comprises the following components in parts by weight:
5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9 parts of glycerol, 4, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9 parts of propylene glycol, 0.4, 0.5, 0.6, 0.7, 0.8 part of xanthan gum, 0.1, 0.15, 0.20, 0.25, 0.30, 0.40 part of allantoin, 2, 3, 4, 5, 6, 7, 8 parts of glycerol stearate 1.2, 1.5, 1.8, 2.0, 2.5 parts, 1.2, 1.5, 1.8, 2.0, 2.5 parts of PEG-10 stearate, 0.4, 0.5, 0.6 part of ethanol phenoxy.
Further, in some embodiments herein, the soothing anti-allergy composition for skin further comprises water.
Further, in some embodiments of the present application, the total parts of the soothing and anti-allergy composition for skin is 100 parts by weight, and the part of water is the total part minus the balance of the sum of prinsepia utilis royle oil, dipotassium glycyrrhizinate, dihydroavenoyl anthranilic acid D, saffron extract, glycerin, propylene glycol, xanthan gum, allantoin, isododecane, glyceryl stearate, PEG-10 stearate, and phenoxyethanol.
In some embodiments of the present application, the total parts by weight of the soothing and anti-allergy composition for skin is 100 parts, wherein the total parts by weight of the soothing and anti-allergy composition for skin is selected from the range of any one of the aforementioned embodiments, including prinsepia utilis royle oil, dipotassium glycyrrhizinate, dihydroavenoylanthranilic acid D, crocus sativus extract, glycerin, propylene glycol, xanthan gum, allantoin, isododecane, glyceryl stearate, PEG-10 stearate, and phenoxyethanol, and the balance is water.
Further, in some embodiments herein, a method of preparing a soothing and anti-allergy composition for skin, comprising the steps of:
and S1, preparing a first solution.
Further, in some embodiments of the present application, 0.05-0.5 parts by mass of dipotassium glycyrrhizinate is heated to 80-95 ℃ and kept warm for 25-45min to obtain a first solution.
Further optionally, in some embodiments of the present application, the dipotassium glycyrrhizinate is heated to 81-94 ℃ and incubated for 26-43min to obtain the first liquid.
Illustratively, heating dipotassium glycyrrhizinate to 81 deg.C, 83 deg.C, 85 deg.C, 88 deg.C, 90 deg.C, and maintaining for 28min, 30min, 35min, 40min, and 42min to obtain first solution.
Further, in some embodiments of the present application, the first liquid is prepared by adding water, glycerin, propylene glycol, xanthan gum, allantoin, and dipotassium glycyrrhizinate, mixing, heating to 80-95 deg.C, and maintaining the temperature for 25-45min.
And S2, preparing second liquid.
Further, in some embodiments herein, 1-10 parts of Prinsepia utilis Royle oil is heated to 80 deg.C-95 deg.C to obtain a second liquid.
Further optionally, in some embodiments of the present application, the prinsepia utilis royle oil is heated to 81 ℃ to 94 ℃ to obtain the second liquid.
Illustratively, prinsepia utilis oil is heated to 82 deg.C, 83 deg.C, 85 deg.C, 87 deg.C, 88 deg.C, 90 deg.C, 92 deg.C, 93 deg.C to obtain a second liquid.
Further, in some embodiments of the present application, isododecane, glyceryl stearate, PEG-100 stearate, and Prinsepia utilis oil are also added to the second liquid, mixed uniformly with the Prinsepia utilis oil, and heated to 80-95 ℃.
And S3, homogenizing.
Further, in some embodiments of the present application, the first liquid and the second liquid are mixed and homogenized, and after the temperature is reduced to 40-50 ℃, 0.1-2 parts of dihydroavenoyl anthranilic acid D and 1-5 parts of saffron extract are added.
Further optionally, in some embodiments of the present application, the first liquid and the second liquid are mixed and homogenized, and after cooling to 41 ℃ to 49 ℃, dihydroavenoyl anthranilic acid D and crocus sativus extract are added.
Illustratively, the first liquid and the second liquid are mixed and homogenized, cooled to 42 deg.C, 43 deg.C, 44 deg.C, 45 deg.C, 46 deg.C, 47 deg.C, and 48 deg.C, and dihydroavenyl anthranilic acid D and crocus sativus extract are added.
Further, in some embodiments of the present application, after the first liquid and the second liquid are mixed and homogenized, phenoxyethanol is further added, and the phenoxyethanol is mixed with the dihydroavenyl anthranilic acid D and the crocus sativus extract uniformly.
It should be noted that the dihydroavenyl anthranilic acid D and the saffron extract are added as raw material components in the form of a solution.
Further, in some embodiments of the present application, the concentration of the dihydroavenoyl anthranilic acid D solution is 1% to 10% by mass.
Further optionally, in some embodiments herein, the dihydroavenoyl anthranilic acid D solution has a mass concentration of 2% to 9%.
Illustratively, the mass concentration of the dihydroavenoyl anthranilic acid D solution is 3%, 4%, 5%, 6%, 7%, 8%.
Further, in some embodiments of the present application, the crocus sativus extract solution has a mass concentration of 1% to 10%.
Further optionally, in some embodiments of the present application, the crocus sativus extract solution has a mass concentration of 2% to 9%.
Illustratively, the mass concentration of the crocus extract solution is 3%, 4%, 5%, 6%, 7%, 8%.
The solvent capable of dissolving the crocus extract solution and the dihydroavenoyl anthranilic acid D is the rest of the crocus extract solution and the dihydroavenoyl anthranilic acid D solution.
Further, in some embodiments of the present application, the conditions for mixing and homogenizing the first liquid and the second liquid are as follows:
2000rpm/min-4000rpm/min，1min-5min。
further optionally, in some embodiments of the present application, the conditions for mixing and homogenizing the first liquid and the second liquid are:
2500rpm/min-3500rpm/min，2min-4min。
illustratively, the conditions for mixing and homogenizing the first liquid and the second liquid are as follows:
2500rpm/min、2800rpm/min、3000rpm/min、3200rpm/min；2min、3min、4min。
further, in some embodiments of the present application, after the first liquid and the second liquid are mixed and homogenized, phenoxyethanol is further added, and the phenoxyethanol is mixed with the dihydroavenyl anthranilic acid D and the crocus sativus extract uniformly.
Further, in some embodiments of the present application, the first liquid and the second liquid are mixed and homogenized, and after the temperature is reduced to 40 ℃ to 50 ℃, phenoxyethanol, a dihydroavenyl anthranilic acid D solution and a crocus sativus extract solution are added to make up the water.
The preparation method of the soothing and anti-allergy composition for skin is simple in steps, and the prepared soothing and anti-allergy composition for skin is good in soothing and anti-allergy effects.
The features and properties of the present application are described in further detail below with reference to examples:
examples 1 to 3 and comparative examples 1 to 4
A soothing and anti-allergy composition for the skin is provided, having the composition of table 1:
TABLE 1
In table 1, the saffron extract (5% solution) refers to a solution of saffron extract as a component of the composition, wherein the mass fraction of the saffron extract in the solution is 5%, and the balance is 1,3-propanediol and water, which are mixed in an arbitrary ratio.
The dihydroavenoyl anthranilic acid D (5% solution) is the dihydroavenoyl anthranilic acid D which is used as the component of the composition in the form of solution, wherein, the mass fraction of the dihydroavenoyl anthranilic acid D in the solution is 5%, and the balance is butanediol and 1,2-pentanediol which are mixed in any proportion.
A negative control group was set. The water content of the stratum corneum of the skin of the negative control group is analyzed and shown in table 2.
TABLE 2
| Water content of negative control group | Before use | After modeling | 30min | 90min |
| Mean value | 35.50 | 37.10 | 32.17 | 33.49 |
| SD value | 6.07 | 4.00 | 5.10 | 5.46 |
| Maximum value | 43.30 | 42.28 | 43.68 | 43.88 |
| Minimum value | 23.78 | 30.68 | 26.18 | 24.88 |
| Median value | 37.89 | 37.19 | 30.53 | 31.70 |
| Normality p value | 0.361 | 0.464 | 0.191 | 0.849 |
| Normalized result | Conform to | Conform to | Conform to | Conform to |
The compositions of examples 1 to 3 and comparative examples 1 to 4 were examined for their performance.
Examples of the experiments
And (3) setting a self front-back control test and a negative control test, acquiring skin moisture content, skin heme content, skin redness value a and VISIA-CR images of 30 persons using the embodiment by a non-invasive test method, carrying out comparative analysis on the data, and verifying the relieving effect of the product.
Product use and test flow
The using part: inside of arm
The using method comprises the following steps: uniformly smearing quantitative samples on a test area
The service cycle is as follows: 90min
Test area: marking position of inner side of arm
Testing time points: before use, after modeling, after using the sample for 30min, and after using the sample for 90 min.
The test flow comprises the following steps:
1) The inner forearm of the subject was randomly marked with 3 skin areas of 3cm x 3cm size as test areas and respectively marked as a negative control group and an experimental group, each group being spaced at least 2cm apart. Photographs of the inner forearm of the subject were taken and the skin hemoglobin content, the skin redness value a, the skin moisture content, the skin moisture loss were measured as the base values before modeling.
2) Respectively carrying out tearing treatment in the test areas of the experimental group and the negative control group by using transparent adhesive tapes, repeatedly tearing 10 times in each area, soaking non-woven fabrics with the size of 3cm multiplied by 3cm in histamine solution with the concentration of 10mg/mL in the test areas of the experimental group and the negative control group after the tearing treatment, taking out the non-woven fabrics after the non-woven fabrics are completely soaked, pasting the non-woven fabrics in the areas of the experimental group and the negative control group, tearing off the non-woven fabrics after waiting for 10min or when the pasted area has erythema, and starting subsequent tests after the surface is dry and has no solution residue. The regions were again evaluated.
And each skin index is used as a basic value after modeling.
3) The test sample is used in the test area of the experimental group with the sample usage amount of 2mg/cm 2 And the negative control group used no sample. The corresponding data tests were performed after the subjects had used.
Data analysis method
Descriptive statistics are made of the measurements of the test areas, including quantity, mean, standard deviation, median, etc. If the test data is normal distribution, performing statistical analysis by adopting a t test method; if the test data is in abnormal distribution, the statistical analysis is carried out by adopting a rank sum test method.
The statistical method adopts two-tail test with test level alpha =0.05
Determination of results
And (4) positive result: before and after the product is used, compared with negative control, the heme content, the skin redness value a and the water content of the stratum corneum in a test area of the product are obviously improved, and the tested sample has a relieving effect.
Negative results: before and after the product is used, compared with negative control, the heme content, the skin redness value a and the water content of the skin stratum corneum in the test area of the product are not obviously improved, and the test sample has no relieving effect.
Test results
1. Analysis of water content of skin horny layer
Skin(s)The water content of horny layer is determined by
CM 825 measures that the greater the value, the higher the stratum corneum moisture content, and conversely the lower the stratum corneum moisture content. The higher the moisture content of the stratum corneum, the better the effect of the sample in increasing the moisture content of the stratum corneum.
The test results of the compositions of examples 1 to 3 and comparative examples 1 to 4 and the negative control group are analyzed as shown in the following table.
TABLE 3 analysis of test results of example 1 and negative control group
| Water content | Before use | After modeling | 30min | 90min |
| Mean negative control group | 35.50 | 37.10 | 32.17 | 33.49 |
| Example 4 mean value | 34.28 | 34.34 | 54.61 | 57.06 |
| Inspection method | Independent t | Independent t | Rank sum test | Independent t |
| Significance p value | ＞0.05 | ＞0.05 | ＜0.05 | ＜0.05 |
| Significance of | Has no obvious effect | Has no obvious effect | Is remarkable in that | Is remarkable in |
And (4) analyzing results:
before and after modeling, the water content of the example 1 and the negative control group has no significant difference, and after the sample is used for 30min and 90min, the water content of the example 1 is significantly higher than that of the negative control group.
TABLE 4 analysis of test results of example 2 and negative control group
And (4) analyzing results:
before and after modeling, the water content of the example 2 and the negative control group has no significant difference, and after the sample is used for 30min and 90min, the water content of the example 2 is significantly higher than that of the negative control group.
TABLE 5 analysis of test results of example 3 and negative control group
| Water content | Before use | After modeling | 30min | 90min |
| Mean of negative control group | 35.50 | 37.10 | 32.17 | 33.49 |
| Example 3 mean value | 36.80 | 34.98 | 55.78 | 58.13 |
| Inspection method | Independent t | Independent t | Independent t | Independent t |
| Significance p value | ＞0.05 | ＞0.05 | ＜0.05 | ＜0.05 |
| Significance of | Has no obvious effect | Has no obvious effect | Is remarkable in that | Is remarkable in that |
And (4) analyzing results:
before and after modeling, the water content of the sample in example 3 is not significantly different from that of the negative control group, and after the sample is used for 30min and 90min, the water content of the sample in example 3 is significantly higher than that of the negative control group.
Skin hemoglobin content analysis
The skin has a high content of hemoglobin
The higher the value of MX 18, the higher the skin hemoglobin content, and conversely the lower the hemoglobin content. The less the skin hemoglobin content, the better the sample's skin irritation-relieving effect.
Analysis of skin hemoglobin content in negative control group
TABLE 6 statistics of skin heme content test results for negative control group
| Hemoglobin content of negative control group | Before use | After modeling | 30min | 90min |
| Mean value | 132.36 | 231.74 | 240.34 | 168.38 |
| SD value | 39.28 | 52.82 | 56.94 | 34.77 |
| Maximum value | 219.00 | 288.80 | 338.60 | 241.80 |
| Minimum value | 100.00 | 164.60 | 153.40 | 115.40 |
| Median value of | 114.80 | 250.70 | 250.30 | 173.00 |
| Normality p value | 0.006 | 0.009 | 0.801 | 0.572 |
| Normality result | Is not in compliance with | Is not in compliance with | Conform to | Conform to |
TABLE 7 analysis of test results of example 1 and negative control group
| Hemoglobin content | Before use | After modeling | 30min | 90min |
| Mean of negative control group | 132.36 | 231.74 | 240.34 | 168.38 |
| Example 4 mean value | 123.14 | 213.24 | 197.90 | 137.12 |
| Inspection method | Rank sum test | Rank sum test | Independent t | Independent t |
| Significance p value | ＞0.05 | ＞0.05 | ＞0.05 | ＜0.05 |
| Significance of | Has no obvious effect | Has no obvious effect | Has no obvious effect | Is remarkable in that |
And (4) analyzing results:
before and after modeling, the content of heme in example 1 and the content of heme in the negative control group are not significantly different, after the sample is used for 30min, the content of heme in example 1 and the negative control group are not significantly different, and after the sample is used for 90min, the content of heme in example 1 and the negative control group are significantly different.
TABLE 8 analysis of the test results of example 2 and negative control group
And (4) analyzing results:
before and after modeling, the heme content of the example 2 and the negative control group has no significant difference, and after the sample is used for 30min and 90min, the heme content of the example 2 is obviously lower than that of the control group, and the heme content of the example 2 and the control group have significant difference.
TABLE 9 analysis of test results of example 3 and negative control group
| Content of heme | Before use | After modeling | 30min | 90min |
| Mean negative control group | 132.36 | 231.74 | 240.34 | 168.38 |
| Example 3 mean value | 136.96 | 221.92 | 217.02 | 139.32 |
| Inspection method | Rank sum test | Rank sum test | Independent t | Independent t |
| Significance p value | ＞0.05 | ＞0.05 | ＜0.05 | ＜0.05 |
| Significance of | Has no obvious effect | Has no obvious effect | Is remarkable in that | Is remarkable in that |
And (4) analyzing results:
before and after modeling, the content of heme in example 3 and the negative control group has no significant difference, and the content of heme in example 3 and the negative control group has significant difference after the samples are used for 30min and 90 min.
Analysis of skin redness value a
The Skin angle redness value a is measured by Skin-Colorimeter CL 400, and the larger the value, the higher the Skin redness, and conversely, the lower the Skin redness. The lower the skin redness value, the better the sample's effect in soothing skin irritation.
Negative control group skin redness value a analysis
TABLE 10 statistics of skin redness values a of negative control groups
TABLE 11 analysis of test results of example 1 and negative control group
| Redness value a | Before use | After modeling | 30min | 90min |
| Mean of negative control group | 7.48 | 11.92 | 11.07 | 7.76 |
| Example 4 mean value | 7.14 | 11.23 | 9.73 | 6.10 |
| Inspection method | Independent t | Independent t | Independent t | Independent t |
| Significance p value | ＞0.05 | ＞0.05 | ＜0.05 | ＜0.05 |
| Significance of | Has no obvious effect | Has no obvious effect | Has no obvious effect | Is remarkable in that |
And (4) analyzing results:
before and after modeling, the redness value a of example 1 and the negative control group were not significantly different, the sample was used for 30min, the redness value a of example 1 and the negative control group were not significantly different, and the redness value a of example was significantly lower than the negative control group after the sample was used for 90 min.
TABLE 12 analysis of test results of example 2 and negative control group
| Redness value a | Before use | After modeling | 30min | 90min |
| Mean of negative control group | 7.48 | 11.92 | 11.07 | 7.76 |
| Example 2 mean value | 7.13 | 11.66 | 7.29 | 4.60 |
| Inspection method | Independent t | Independent t | Rank sum test | Independent t |
| Significance p value | ＞0.05 | ＞0.05 | ＜0.05 | ＜0.05 |
| Significance of | Has no obvious effect | Has no obvious effect | Is remarkable in that | Is remarkable in that |
TABLE 13 analysis of test results of example 3 and negative control group
And (4) analyzing results:
before and after modeling, the redness value a of example 3 was not significantly different from that of the negative control group, and after the sample was used for 30min and the sample was used for 90min, the redness value a of example 3 was significantly lower than that of the negative control group and significantly different from that of the negative control group.
TABLE 14 analysis of results of moisture content of horny layer of comparative examples 1 to 4 and negative control group
And (4) analyzing results: before and after modeling, and after the samples were used for 30min and 90min, there was no significant difference between the water content of the control examples 1-4 and the negative control group.
TABLE 15 analysis of results for control examples 1-4 and the negative control heme content
And (4) analyzing results: before and after modeling, and after the samples were used for 30min and 90min, there was no significant difference between the heme contents of comparative examples 1-4 and the negative control group.
Table 16 comparative examples 1-4 and negative control skin redness value a analysis
And (4) analyzing results: the blood skin redness values a of comparative examples 1-4 were not significantly different from the negative control group before and after modeling, and after 30min and 90min using the samples.
In conclusion, the soothing and anti-allergy composition for skin of the present application is superior in soothing and anti-allergy to comparative examples 1 to 4.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims (10)
1. A soothing and anti-allergy composition for skin is characterized by comprising the following components in parts by weight:
1-10 parts of prinsepia utilis royle oil; 0.05-0.5 part of dipotassium glycyrrhizinate; 0.1-2 parts of dihydrooat acyl anthranilic acid D; 1-5 parts of crocus sativus extract.
2. A soothing anti-sensitivity composition for skin according to claim 1, further comprising: glycerol, propylene glycol, xanthan gum, allantoin, isododecane, glyceryl stearate, PEG-10 stearate, and phenoxyethanol.
3. A soothing and anti-sensitivity composition for skin according to claim 2,
the soothing and anti-allergy composition for the skin comprises the following components in parts by mass:
5-10 parts of glycerol, 3-10 parts of propylene glycol, 0.1-1.0 part of xanthan gum, 0.05-0.5 part of allantoin, 1-10 parts of isododecane, 1-3 parts of glycerol stearate, 1-3 parts of PEG-10 stearate and 0.2-0.8 part of phenoxyethanol.
4. A soothing and anti-sensitivity composition for skin according to claim 3,
the soothing anti-allergy composition for skin further comprises water.
5. A soothing anti-sensitivity composition for skin according to claim 4,
the total parts of the soothing and anti-allergy composition for the skin are 100 parts by mass, and the part of the water is the sum of the total parts minus the balance of the prinsepia utilis royle oil, the dipotassium glycyrrhizinate, the dihydroavenoyl anthranilic acid D, the saffron extract, the glycerin, the propylene glycol, the xanthan gum, the allantoin, the isododecane, the glyceryl stearate, the PEG-10 stearate and the phenoxyethanol.
6. A method of preparing a soothing and anti-allergy composition for skin, comprising:
heating 0.05-0.5 part of dipotassium glycyrrhizinate to 80-95 ℃ according to the mass parts, and preserving heat for 25-45min to obtain a first solution;
heating 1-10 parts of prinsepia utilis royle oil to 80-95 ℃ to obtain second liquid;
mixing the first liquid and the second liquid, homogenizing, cooling to 40-50 deg.C, adding 0.1-2 parts of dihydroavenyl anthranilic acid D and 1-5 parts of stigma croci Sativi extract.
7. A method of preparing a soothing and anti-sensitivity composition for skin as claimed in claim 6, comprising:
adding water, glycerol, propylene glycol, xanthan gum, allantoin and the dipotassium glycyrrhizinate into the first solution, uniformly mixing, heating to 80-95 ℃, and keeping the temperature for 25-45min.
8. A method of preparing a soothing and anti-sensitivity composition for skin as claimed in claim 6, comprising:
and adding isododecane, glyceryl stearate and PEG-100 stearate into the second liquid, uniformly mixing with the prinsepia utilis royle oil, and heating to 80-95 ℃.
9. A method of preparing a soothing and anti-sensitivity composition for skin as claimed in claim 6, comprising:
mixing the first liquid and the second liquid, homogenizing, adding phenoxyethanol, and mixing with the dihydroavenyl anthranilic acid D and the crocus sativus extract.
10. A cosmetic comprising the soothing anti-allergy composition for skin of any one of claims 1 to 5 or the soothing anti-allergy composition for skin prepared by the preparation method of the soothing anti-allergy composition for skin of any one of claims 6 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211072847.1A CN115634174B (en) | 2022-09-02 | 2022-09-02 | Soothing and antiallergic composition for skin, preparation method thereof and cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211072847.1A CN115634174B (en) | 2022-09-02 | 2022-09-02 | Soothing and antiallergic composition for skin, preparation method thereof and cosmetic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115634174A true CN115634174A (en) | 2023-01-24 |
| CN115634174B CN115634174B (en) | 2023-09-19 |
Family
ID=84940475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211072847.1A Active CN115634174B (en) | 2022-09-02 | 2022-09-02 | Soothing and antiallergic composition for skin, preparation method thereof and cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115634174B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102406576A (en) * | 2011-10-28 | 2012-04-11 | 何黎 | Prinsepia utilis Royle oil-containing functional skin care product and preparation method thereof |
| CN107233223A (en) * | 2017-06-16 | 2017-10-10 | 湖南御家化妆品制造有限公司 | Control induction melanin target composition and its application |
| FR3053589A1 (en) * | 2016-07-07 | 2018-01-12 | Caster | USE OF COMPOSITIONS FOR MATURE SKINS |
| CN107714531A (en) * | 2017-09-26 | 2018-02-23 | 湖南御家化妆品制造有限公司 | Anti-allergy relieving composition and application thereof |
| CN113440461A (en) * | 2021-06-23 | 2021-09-28 | 植物医生(广东)生物科技有限公司 | Soothing and allergy-reducing composition and application thereof |
-
2022
- 2022-09-02 CN CN202211072847.1A patent/CN115634174B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102406576A (en) * | 2011-10-28 | 2012-04-11 | 何黎 | Prinsepia utilis Royle oil-containing functional skin care product and preparation method thereof |
| FR3053589A1 (en) * | 2016-07-07 | 2018-01-12 | Caster | USE OF COMPOSITIONS FOR MATURE SKINS |
| CN107233223A (en) * | 2017-06-16 | 2017-10-10 | 湖南御家化妆品制造有限公司 | Control induction melanin target composition and its application |
| CN107714531A (en) * | 2017-09-26 | 2018-02-23 | 湖南御家化妆品制造有限公司 | Anti-allergy relieving composition and application thereof |
| CN113440461A (en) * | 2021-06-23 | 2021-09-28 | 植物医生(广东)生物科技有限公司 | Soothing and allergy-reducing composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115634174B (en) | 2023-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109044915B (en) | Infant hip-protecting cream and preparation process thereof | |
| WO2021136275A1 (en) | Multi-stage fat-protecting skincare composition for protecting skin barrier of infants | |
| CN111557886B (en) | Plant-nourishing efficient moisturizing cream and preparation method thereof | |
| CN106551870A (en) | A kind of compositionss with crease-resistant skin lightening effect, facial film and preparation method thereof | |
| CN115487118B (en) | White tea essential oil nanoemulsion with anti-allergy and soothing effects and preparation method thereof | |
| CN114632058A (en) | High-concentration low-irritation salicylic acid gel for treating acne and preparation method and application thereof | |
| CN110638727A (en) | Infant hip-protecting composition and preparation method and application thereof | |
| CN104398399A (en) | Composite glycopeptide breast beauty cream and preparation method thereof | |
| CN109431842B (en) | Eczema cream for children | |
| CN104800269A (en) | Traditional Chinese medicine external-use cream used for treating psoriasis and preparation method thereof | |
| CN115634174A (en) | Soothing and anti-allergy composition for skin, preparation method thereof and cosmetic | |
| CN116251047B (en) | Oil-control hair-washing agent containing burdock root extract and preparation method thereof | |
| CN116350550A (en) | Face cream with moisturizing and soothing effects and preparation method thereof | |
| CN114432207B (en) | Long-acting moisturizing repair composition, repair cream and preparation method of repair cream | |
| CN113081924B (en) | Antioxidant composition, preparation method and application | |
| CN115919686A (en) | Skin soothing lotion for enhancing skin barrier and preparation method thereof | |
| JPS59216812A (en) | Hair restoring agent | |
| PT2011504E (en) | Skin cream for treatment and/or cleaning of skin for neurodermitis | |
| CN111888275B (en) | Composition and preparation method and application thereof | |
| CN113576994A (en) | Composition with synergistic moisturizing and relieving effects, cosmetic and preparation method thereof | |
| CN113499271A (en) | Anti-allergy compound and preparation method and application thereof | |
| CN114306194A (en) | Freckle-removing cosmetic composition containing umbilical cord blood extract, freckle-removing cream and preparation method thereof | |
| CN105997609A (en) | Moisture preserving composition and preparation method thereof | |
| CN102688178B (en) | Application of rape bee pollen extract in anti-aging skin care products | |
| CN113827509B (en) | Coenzyme Q10 eye cream and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |